PMC:7553377 / 23576-24257 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/7553377","sourcedb":"PMC","sourceid":"7553377","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7553377","text":"An analysis was performed to evaluate the relationship between the therapies that were used for COVID-19 and liver function tests. When separate comparisons were performed between the patients who received hydroxychloroquine, azithromycin, other antibiotics, oseltamivir and who did not receive these agents, no significant differences of AST or ALT were found. However in patients who received favipiravir therapy, there was a significant change in both AST and ALT values (p \u003c 0.05). Patients who had favipiravir treatment had increased AST and ALT levels at follow-up, however there was no significant change in L/S between the patients who received favipiravir and who did not.","tracks":[]}